anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Edluar, like other sedative-hypnotic drugs, CNS depressant effects. Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. Dosage adjustments of Edluar and of other concomitant CNS depressants may be necessary when Edluar is administered with such agents because of the potentially additive effects. The use of Edluar with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended [see Dosage and Administration (2.3)].

The risk of next-day psychomotor impairment, including impaired driving, is increased if Edluar is taken with less than a full night of sleep remaining (7 to 8 hours); if a higher than the recommended dose is taken; if co-administered with other CNS depressants; or if co-administered with other drugs that increase the blood level of zolpidem. Patients should be cautioned against driving and other activities requiring complete mental alertness if Edluar is taken in these circumstances. 

Because Edluar can cause drowsiness and a decreased level of consciousness, patients, particularly the elderly, are at higher risk of falls.
The present invention relates to the preparation field at active Chinese drug component position, disclose a kind of root bark of Chinese wolf-berry active site and its preparation method and application. After described preparation method comprises the steps: that S1. pulverizes the root bark of Chinese wolf-berry, water extracts, then extract is concentrated, adds ethanol to carry out alcohol precipitation, gets supernatant concentration and obtains stoste; S2. stoste is passed through to macroporous absorbent resin, collect eluent, evaporate to dryness, the concentrated sample 1 that to obtain; S3. sample 1 is adsorbed by strongly acidic cation-exchange, first wash resin column with water, then use ammoniacal liquor wash-out, collect ammoniacal liquor eluent, concentrated sample 2; S4. sample 2 is adsorbed by strong-base anion-exchange resin, collect water elution liquid, concentrate drying obtains root bark of Chinese wolf-berry active site. The root bark of Chinese wolf-berry active site alkaloid activity component content that the present invention prepares is higher, can be used for the diseases such as prevention and treatment diabetes, obesity, high fat of blood.
Adaptation to hypoxia has attracted much public interest because of its clinical significance. However, hypoxic adaptation in the body is complicated and difficult to fully explore. To explore previously unknown conserved mechanisms and key proteins involved in hypoxic adaptation in different species, we first used a yeast model for mechanistic screening. Further multi-omics analyses in multiple species including yeast, zebrafish and mice revealed that glycerophospholipid metabolism was significantly involved in hypoxic adaptation with up-regulation of lysophospholipid acyltransferase (ALE1) in yeast, a key protein for the formation of dipalmitoyl phosphatidylcholine [DPPC (16:0/16:0)], which is a saturated phosphatidylcholine. Importantly, a mammalian homolog of ALE1, lysophosphatidylcholine acyltransferase 1 (LPCAT1), enhanced DPPC levels at the cell membrane and exhibited the same protective effect in mammalian cells under hypoxic conditions. DPPC supplementation effectively attenuated growth restriction, maintained cell membrane integrity and increased the expression of epidermal growth factor receptor under hypoxic conditions, but unsaturated phosphatidylcholine did not. In agreement with these findings, DPPC treatment could also repair hypoxic injury of intestinal mucosa in mice. Taken together, ALE1/LPCAT1-mediated DPPC formation, a key pathway of glycerophospholipid metabolism, is crucial for cell viability under hypoxic conditions. Moreover, we found that ALE1 was also involved in glycolysis to maintain sufficient survival conditions for yeast. The present study offers a novel approach to understanding lipid metabolism under hypoxia and provides new insights into treating hypoxia-related diseases.
We have successfully sequenced and cloned the gene expressing the Major Surface Protein 5 (MSP5) of  A. phagocytophilum.  The recombinant MSP5 (rMSP5) protein has been tested using sera from humans and dogs infected with  A. phacytophilum.  The polypeptide has been found to be immunogenic and useful as a diagnostic test antigen. The polypeptide antigen of the subject invention can provide the basis of a diagnostic assay that would allow the rapid, in-house, laboratory diagnosis of infection with  A. phagocytophilum  using a sample (e.g., serum, plasma, or whole blood) from an infected human or animal. Additionally, the subject invention provides methods of detecting the presence of  A. phagocytophilum  in biological or environmental samples utilizing antibodies provided by the subject invention. Furthermore, the use of the single antigen in the diagnosis of this important disease offers many advantages including enhanced test specificity, ease of testing and consistency of results using synthetically produced test antigens instead of cultured, whole organisms.
Some patients with CML can withdraw from TKIs after treatment, and the mechanism might be related to the effect of memory NK cells on anti-Ph+ leukemic stem cells (LSCs). Dasatinib affects immune through several pathways including the expression of PD1 in immune cells. Our previous work showed increased NKG2C+ NK cells were found in cases with CMV-DNA+ who suffered Ph+ leukemia and received Dasatinib, and these memory NK cells have anti-LSCs activity. We hypothesize that: CMV infection activates NKG2C+ memory NK cells proliferation; Dasatinib down-regulates the expression of PD1 in PD1+NKG2C+ NK cell subsets and then enhances anti-LSCs activity of these cells. In this study, the effect of Dasatinib on CMV-activated NKG2C+ cell subsets and its mechanism will be studies. Besides, the different NKG2C+ cell subsets on LSCs will be compared. This study might be helpful to clarify the mechanism of TKI withdrawal and to offer foundation for CMV and Ph+ ALL treatment strategies
This randomized controlled trial will be conducted in Zhangwu People's Hospital in Liaoning Province, Qingtongxia People's Hospital in Ningxia Hui Autonomous Region and Dianjiang People's Hospital in Chongqing City. Eligible and consenting stroke in patients with residual disability will be randomized into the intervention group or control group after they have passed the acute care stage and approved by their physicians to be recruited into the study. Standardized baseline assessments for all patients include Barthel Index (activities of daily living), modified Rankin Scale, and other demographic, disease history, lifestyle, and health information. Nurses in the county hospital will be trained by rehabilitation specialists and will in turn train the family caregivers of patients in the intervention group with the aid of an easy-to-understand picture-rich rehabilitation manual, specially designed for this study. The content of training is based on 10 domains in the Barthel Index, which can be classified into 3 groups: mobility, self-care, and toileting. Nurses will do the telephone based follow-up to patients at approximately 2, 4, and 8 weeks post-discharge to provide follow-up care and consultation. Follow-up evaluation of all patients will be conducted by researchers not involved in the intervention. Pre-discharge evaluation including Barthel Index, modified Rankin Scale and Functional Ambulation Category will be conducted face to face with patients, . 3 months and 6 months evaluation will be conducted via telephone based interview.3 months evaluation includes living condition, Barthel Index ,modified Rankin Scale, hospitalization condition and medicine usage. Based on 3 months evaluation, 6 months evaluation includes additional measures: Functional Ambulation Classification, EQ-5D, 9-item Patient Health Questionnaire, physical examination and caregiver burden. Primary outcome will be the Barthel Index score at 6-month after hospital discharge. The study will be conducted in 2 phases: 1) pilot study (Lasting for 2 months, 30 patients in Zhangwu People's Hospital and 30 patients in Qingtongxia People's hospital); and 2) main study (Lasting for 15 months, 100 patients in Zhangwu People's Hospital, 100 patients in Qingtongxia People's hospital and 60 patients in Dianjiang People's Hospital). Information from pilot study will be used for refinement of the intervention and study implementation. Patients in the pilot study will be followed until the end of the study, resulting in a total of 320 patients.

Primary Hypothesis: The innovative caregiver-delivered nurse-organized rehabilitation intervention, compared to usual care, will significantly improve physical functioning of disabled stroke patients in rural China, as measured by the Barthel Index (activities of daily living) at six months after hospital discharge.
The Aim is to define the contribution of genetic variation to the interindividual variability in response to β-blockade. The rationale for the study is as follows: Beta-blockers prevent the activation of β-ARs and thus form the cornerstone of treatment of pathological states such as congestive heart failure and coronary artery disease. Functional polymorphisms in cardiac beta-receptors have been shown to determine response to β-blocker therapy. A physiologic stimulus such as exercise causes sympathetic stimulation and activation of the cardiac β-ARs and genotypic differences in response to β-blockers are magnified under states of heightened sympathetic activity. Thus, in addition to measuring the response to β-blockers at rest, we will also determine the response to β-blockade after sub-maximal exercise on a supine bicycle ergometer. Genetic variations that may alter sensitivity to a beta blocker will be sought.
NEW MATERIAL:A compound shown by formula I (R is pheoxy-substituted alkyl) or a salt thereof. EXAMPLE:1-(2-Phenoxyethoxy)carbonylimidazol[1,5-a]pyridin-3-(2H)-one. USE:A remedy for amnesia and presbyophrenia. The titled substance has improv ing effects on oxygen deficient state and symptoms resulting from it. Consequent ly, it has cerebrobascular vasodilating action and improving action on cerebral function disorder. PREPARATION:A compound shown by formula II is reacted with a compound shown by the formula ROH to give a compound shown by formula I.
Each patient received two prostheses: 1) Conventional Maxillary and mandibular complete denture. 2) 3D printed complete Maxillary and mandibular complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing denture then the other type of denture was delivered and used for another 3 months.
To provide a novel anthranilamide compound or its salt which is useful as a pesticide; a process for its production; and a pesticide containing such a compound as an active ingredient.     An anthranilamide compound represented by the formula (I) or its salt. In the formula, R1 is halogen, alkyl, haloalkyl, etc.; each of R2 and R3 which are independent of each other, is halogen, alkyl, haloalkyl, etc.; A is alkyl substituted by Y; Y is C3-4 cycloalkyl which may be substituted by at least one substituent selected from the group consisting of halogen, alkyl and haloalkyl; m is from 0 to 4; n is 0 or 1; and q is from 0 to 4.   (see formula I)
BACKGROUND AND AIM OF THE STUDY: There are still patients with hepatitisC in Spain who have yet to be diagnosed, but their clinical profile is unclear. In 2021, 21.93% of patients diagnosed had cirrhosis and were mostly treatment-naïve.
METHODS: This sub-analysis describes the clinical profile of the 60Spanish treatment-naïve patients with compensated cirrhosis who were included in the CREST study.
MAJOR RESULTS: Sixty percent of patients were male, median age 56years, and 33% had a history of drug use. Almost three-quarters (71.3%) had more than one comorbidity and 78.3% took concomitant medication. At treatment initiation, median platelet count was 139×103/μL and FibroScan® 17kPa. No virological failure was observed and no patient discontinued treatment due to adverse events. No clinically significant changes were noted during or after treatment in the median platelet, albumin, bilirubin, and transaminase levels.
CONCLUSIONS: Treatment with glecaprevir/pibrentasvir for 8weeks in this cohort of treatment-naïve patients with compensated cirrhosis in Spain was safe and effective. This information reinforces the use of this short antiviral regimen even when there is compensated cirrhosis, simplifying the approach to hepatitisC among those patients still to be diagnosed and treated in Spain.
The invention provides an anti-LILRB 1 antibody and application thereof, wherein the anti-LILRB 1 antibody comprises a heavy chain variable region and a light chain variable region, and the CDR1 of the heavy chain variable region comprises an amino acid sequence shown as SEQ ID NO. 3; CDR2 of the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 4; CDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID NO. 5; CDR1 of the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 6; CDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID NO. 7; CDR3 of the light chain variable region includes the amino acid sequence shown as SEQ ID NO. 8. The anti-LILRB 1 antibody specifically binds to a LILRB1 protein expressed on the cell surface, and can block ligand binding to LILRB1.
Since limb bleeding has been well managed by extremity tourniquets, the management of exsanguinating torso hemorrhage (TH) has become a hot issue both in military and civilian medicine. Conventional hemostatic techniques are ineffective for managing traumatic bleeding of organs and vessels within the torso due to the anatomical features. The designation of noncompressible torso hemorrhage (NCTH) marks a significant step in investigating the injury mechanisms and developing effective methods for bleeding control. Special tourniquets such as abdominal aortic and junctional tourniquet and SAM junctional tourniquet designed for NCTH have been approved by FDA for clinical use. Combat ready clamp and junctional emergency treatment tool also exhibit potential for external NCTH control. In addition, resuscitative endovascular balloon occlusion of the aorta (REBOA) further provides an endovascular solution to alleviate the challenges of NCTH treatment. Notably, NCTH cognitive surveys have revealed that medical staff have deficiencies in understanding relevant concepts and treatment abilities. The stereotypical interpretation of NCTH naming, particularly the term noncompressible, is the root cause of this issue. This review discusses the dynamic relationship between TH and NCTH by tracing the development of external NCTH control techniques. The authors propose to further subdivide the existing NCTH into compressible torso hemorrhage and NCTH' (noncompressible but REBOA controllable) based on whether hemostasis is available via external compression. Finally, due to the irreplaceability of special tourniquets during the prehospital stage, the authors emphasize the importance of a package program to improve the efficacy and safety of external NCTH control. This program includes the promotion of tourniquet redesign and hemostatic strategies, personnel reeducation, and complications prevention.
666,463. Hemophilus pertussis antigens. SHARP & DOHME, Inc. Nov. 22, 1949 [June 28, 1949], No. 29909/49. Class 81 (i). A pertussis toxin-containing solution is detoxified by exposing it to a solution of an aliphatic alcohol having 2 to 4 carbon atoms in its molecule, the alcoholic concentration being 20 to 80 per cent by volume. According to an example, H. pertussis is grown for 48 hours at 37‹ C. on a casein hydrolysate base medium. The culture is centrifuged and the pertussis cells suspended in distilled water. The suspension is subjected to sonic oscillations and the supernatant liquid is centrifugally separated from the cell debris. The solution is cooled to 2-5‹ C. and anhydrous ethanol having a temperature of -50‹ C. is added until the alcohol concentration is 40 per cent by volume. The mixture is maintained at -10‹ C. for 24 hours. After dilution with distilled water to an alcohol concentration of 4 per cent, potash alum is added. After standing, the resulting precipitate is filtered, washed with distilled water and suspended in an isotonic phosphate buffer solution having a pH of 7.4. According to other examples ethanol is replaced by propyl, isopropyl or butyl alcohol. Specification 643,546 is referred to.
The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the FcεRI receptor by a chimeric cytotoxin FC 2′-3 -PE 40 . A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE 40 —a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in  E. coli , specifically and efficiently kills mouse mast cell lines expressing the FcεRI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of FcεRI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for FcεRI expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin  Pseudomonas  exotoxin (PE). This  Pseudomonas  exotoxin is a product of  Pseudomonas aeruginosa . The present invention also relates to a method for the preparation of said protein. This chimeric protein is prepared by genetically fusing the Fc region of the mouse IgE molecule to PE 40 , a truncated form of PE lacking the cell binding domain. The present invention also provides pharmaceutical compositions, for the treatment of allergic diseases and for the treatment of hyperplasias and malignancies, comprising as an active ingredient the above mentioned chimeric protein and a conventional adjuvant product.
The present invention relates to injection containing a calcium channel blocker for intravenous injection after diltiazem dilution, which comprises salt diltiazem as an active compound, a solvent and medicinal formulation auxiliary materials. Per milliliter injecting solution contains 1 to 100 milligrams of an active compound. The solvent is a non water composite solvent and is a mixture of ethanol and polyatomic alcohol. The polyatomic alcohol is propanediol, glycerol or a mixture of propanediol and glycerol. The volume ratio of the ethanol is 40 to 80% for the composite solvent. By a long time test, every exploration index of the injection under the condition of 25 DEG C conforms to the requirements of a quality standard draft. Thus, the injection is stable under the condition of the existing package.
UNLABELLED: Background: The evolution of axillary management in breast cancer has witnessed significant changes in recent decades, leading to an overall reduction in surgical interventions. There have been notable shifts in practice, aiming to minimize morbidity while maintaining oncologic outcomes and accurate staging for newly diagnosed breast cancer patients. These advancements have been facilitated by the improved efficacy of adjuvant therapies.
OBJECTIVE: To compare the outcomes of axillary lymph node dissection (ALND) and loco-regional axillary radiotherapy (ART) on lymphedema and disease recurrence in locally advanced breast cancer (LABC) cases that have shown a downstaging of their axillary status after neoadjuvant chemotherapy (NACT). Material and Methods: Sixty patients with LABC with an initial cN1-2 disease showed a downstaging of their axillary status to cN0 after NACT. They were randomized into two groups. The first group (the control group) underwent ALND, while the second group (the study group) had a sentinel lymph node biopsy (SLNB) and post-operative ART. Patients with failed SLNB or positive SLNB were excluded. All patients were followed up for loco-regional recurrence and lymphedema for at least one year. Results: No Statistical significance was found between both groups regarding loco-regional recurrence. There was a higher rate of arm lymphedema in the control group. Lymphedema was found in 46.7% of patients who underwent ALND, compared to 13.4% in the study group (patients with SLNB and radiotherapy).
CONCLUSION: Axillary radiation after SNLB has shown no difference regarding axillary recurrence when compared to ALND. However, our results were in favor of radiation concerning lymphedema. With all the ongoing research aiming at reducing axillary surgery, this study could be an initiative for a new strategy in LABC.
KEY MESSAGE: With all the ongoing research aiming at reducing axillary surgery, this study could be an initiative for a new strategy in LABC for patient who have shown down-staging of their axillary status after NACT. Radiotherapy can show better results in the long term with regards lymphedema.
Sediments underlying marine hypoxic zones are huge sinks of unreacted complex organic matter, where despite acute O2 limitation, obligately aerobic bacteria thrive, and steady depletion of organic carbon takes place within a few meters below the seafloor. However, little knowledge exists about the sustenance and complex carbon degradation potentials of aerobic chemoorganotrophs in these sulfidic ecosystems. We isolated and characterized a number of aerobic bacterial chemoorganoheterotrophs from across a ~ 3 m sediment horizon underlying the perennial hypoxic zone of the eastern Arabian Sea. High levels of sequence correspondence between the isolates' genomes and the habitat's metagenomes and metatranscriptomes illustrated that the strains were widespread and active across the sediment cores explored. The isolates catabolized several complex organic compounds of marine and terrestrial origins in the presence of high or low, but not zero, O2. Some of them could also grow anaerobically on yeast extract or acetate by reducing nitrate and/or nitrite. Fermentation did not support growth, but enabled all the strains to maintain a fraction of their cell populations over prolonged anoxia. Under extreme oligotrophy, limited growth followed by protracted stationary phase was observed for all the isolates at low cell density, amid high or low, but not zero, O2 concentration. While population control and maintenance could be particularly useful for the strains' survival in the critically carbon-depleted layers below the explored sediment depths (core-bottom organic carbon: 0.5-1.0% w/w), metagenomic data suggested that in situ anoxia could be surmounted via potential supplies of cryptic O2 from previously reported sources such as Nitrosopumilus species.
PURPOSE:To provide an antibacterial agent containing a specific flavone compound as an active component and exhibiting suppressing effect against indigenous dermatic bacteria. CONSTITUTION:A compound of formula (R3, R5-R8 and R2'-R5' are H or OH; R6' is H) is used as an active component of the objective antibacterial agent at an amount of 0.01-1wt% of the whole composition. The compound of formula is present in plant and is produced by extracting the plant with a proper solvent or by a synthetic means comprising the condensation of O- hydroxyacetophenone or its hydroxyl-substitution product with benzoyl chloride or its hydroxyl-substitution product and the cyclization of the resultant O- benzoxyacetophenone or corresponding hydroxyl-substitution product. It is effective against Staphylococcus epidermis which is an indigenous dermatic bacterium. The agent is useful for the prevention and remedy of dermatic diseases such as acne vulgaris (pimple). The compound is added with a base and additives and is used in the form of solution, emulsion, powder, dispersion, etc.